{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:42Z","timestamp":1792839762669,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.cgh.2015.05.029","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T16:58:49Z","timestamp":1433437129000},"page":"2342-2349.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome"],"prefix":"10.1016","volume":"13","author":[{"given":"Onur","family":"Keskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"T\u00fcz\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Zachou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xheni","family":"Deda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Heidrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcen","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendal","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"G\u00fcrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Idilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Bozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Yurdaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2015.05.029_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0032-1323629","article-title":"Treatment of chronic delta hepatitis","volume":"32","author":"Yurdaydin","year":"2012","journal-title":"Sem Liver Dis"},{"key":"10.1016\/j.cgh.2015.05.029_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","article-title":"Two-year interferon therapy with or without ribavirin in chronic delta hepatitis","volume":"10","author":"G\u00fcn\u015far","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cgh.2015.05.029_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2893.1996.tb00002.x","article-title":"long-term interferon-\u03b1 treatment of children with chronic hepatitis delta: a multicentre study","volume":"3","author":"Di Marco","year":"1996","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2015.05.029_bib4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1365-2893.2007.00875.x","article-title":"A\u00a0pilot study of two years of interferon in patient with chronic delta hepatitis","volume":"14","author":"Yurdaydin","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2015.05.029_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs. lamivudine\u00a0+ interferon vs. interferon","volume":"15","author":"Yurdayd\u0131n","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2015.05.029_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib7","first-page":"1039A","article-title":"Delta hepatitis may require prolonged treatment with interferon (abstr)","volume":"54","author":"Kaba\u00e7am","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0016-5085(99)70409-9","article-title":"Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy","volume":"117","author":"Lau","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2015.05.029_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4318\/tjg.2012.0538","article-title":"Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis","volume":"23","author":"Kaba\u00e7am","year":"2012","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.cgh.2015.05.029_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa 2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B surface antigen levels: a guide to sustained response to pegylated interferon alfa 2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2015.05.029_bib13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1478-3231.2009.02140.x","article-title":"Quantitative HBsAg and HDV RNA levels in chronic delta hepatitis","volume":"30","author":"Zachou","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2015.05.029_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/bimj.200710415","article-title":"Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection","volume":"50","author":"Ruopp","year":"2008","journal-title":"Biom J"},{"key":"10.1016\/j.cgh.2015.05.029_bib15","first-page":"974A","article-title":"Early on-treatment HDV RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta (abstr)","volume":"60","author":"W\u00f6bse","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib16","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematic modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jhep.2013.07.017","article-title":"Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype","volume":"59","author":"Brunetto","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2015.05.029_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3851\/IMP2381","article-title":"Efficacy of pegylated interferon-\u03b1 treatment for 24 months in chronic delta hepatitis and predictors of response","volume":"18","author":"Karaca","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cgh.2015.05.029_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib20","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.cgh.2014.01.043","article-title":"Effects of polymorphisms in interferon \u03bb3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection","volume":"12","author":"Yilmaz","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2015.05.029_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.dld.2013.11.006","article-title":"No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance","volume":"46","author":"Visco-Comandini","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2015.05.029_bib22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alfa-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib23","first-page":"222A","article-title":"96 weeks of pegylated interferon alfa-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 Study (abstr)","volume":"58","author":"Wedemeyer","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2015.05.029_bib24","article-title":"Collaborative study to establish a World Health Organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays. Expert Committee Meeting on biological standardization","author":"Chudy","year":"2013","journal-title":"WHO\/BS\/2013.2227. Geneva"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515007648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356515007648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:12:30Z","timestamp":1762549950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356515007648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1542356515007648"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2015.05.029","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725536694.793507269","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2015.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}